peoplePerson
Paul G. Richardson
Led the DETERMINATION trial and many of the myeloma drug approvals of the past two decades.
Principal investigator on pivotal trials of bortezomib, lenalidomide-based regimens and newer agents; led DETERMINATION, which tested delayed versus upfront transplant in the lenalidomide era.
Role
Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center
Institution
Specialisms
Multiple myelomaNovel agentsTransplant-deferral strategies
Profiles
| Title | Journal | Year |
|---|---|---|
| Triplet therapy, transplantation, and maintenance until progression in myeloma | New England Journal of Medicine | 2022 |